James Robinson (biopharmacist)

James (Jim) Robinson is the vice chair of the Coalition for Epidemic Preparedness Innovations (CEPI).

James Robinson
Scientific career
InstitutionsG.D. Searle, LLC
Sanofi Pasteur
Novavax
Merck
Coalition for Epidemic Preparedness Innovations (CEPI)

Robinson manages the CEPI manufacturing strategy for a COVID-19 vaccine.[1]

Career

Robinson began his career as a biochemical engineer with G.D. Searle and worked at various companies before becoming the head of technical support for Merck's vaccine, biologics and sterile manufacturing in 2010.[2][3]

In 2017, Robinson began serving on CEPI's scientific advisory board. He was made vice-chair in 2019.[3]

On February 16, 2022, Robinson was awarded a two-year, $340,000 grant by the Arnold Ventures Foundation to study biosimilars to determine potential cost savings from wider use of them.[4]

References
  1. Heath, Elizabeth Weise and David (26 April 2020). "'Our moon shot': The world needs a coronavirus vaccine ASAP. Despite drugmakers billion-dollar bets, one might not be available for years". USA TODAY. Retrieved 2020-05-20.{{cite web}}: CS1 maint: url-status (link)
  2. Dumiak, Michael (2017). "A Crisis Gives You WIngs". IAVI Report. Retrieved 2020-05-20.{{cite web}}: CS1 maint: url-status (link)
  3. Wright, Rob (27 March 2020). "The Little-Known Coalition Tasked With Saving The World From COVID-19". Life Science Leader. Retrieved 2020-05-20.{{cite web}}: CS1 maint: url-status (link)
  4. MacNeil, Matt (2022-02-16). "James Robinson receives grant to study biosimilars". UC Berkeley Public Health. Retrieved 2023-04-06.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.